Observational studyDiabetes2021

Empagliflozin Treatment Is Associated With Improvements in Cardiac Energetics and Function and Reductions in Myocardial Cellular Volume in Patients With Type 2 Diabetes.

Sharmaine Thirunavukarasu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.